Join
Live feed
·
PRReleasevia Quantisnow
Candel Therapeutics Inc. logo

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

ByQuantisnow·Wall Street's wire, on your screen.
CADL· Candel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CADL (Candel Therapeutics Inc.) and more on Quantisnow.